Fondaparinux sodium

Cas No.:	114870-03-0
SMILES:	O[C@H]1[C@@H]([C@H](O[C@@]([H])([C@@H]1NS([O-])(=O)=O)O[C@@H]2[C@H](O[C@]([H])([C@@H]([C@H]2O)O)O[C@H]3[C@@H]([C@H]([C@H](O[C@@H]3COS([O-])(=O)=O)O[C@@]4([C@@H](O[C@H]([C@@H]([C@H]4O)OS([O-])(=O)=O)O[C@]5([C@@H]([C@H]([C@H](O[C@@H]5COS([O-])(=O)=O)OC)NS([O-])(=O)=O)O)[H])C([O-])=O)[H])NS([O-])(=O)=O)OS([O-])(=O)=O)C([O-])=O)COS([O-])(=O)=O)O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Formula:	C31H43N3Na10O49S8
M.Wt:	1728.08
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
Target:	Factor Xa[1]
In Vivo:	Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation[1].
In Vitro:	Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC50 values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs)[2].
References:	[1]. Bauer KA. et al. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S14-7. [2]. Ben-Hadj-Khalifa S, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis. 2011 Jul;22(5):369-73.